M. Helmstädter

发表

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice

S. Müller, D. Merk, M. Schröder, 2020, Communications Chemistry.

Development and in vitro Profiling of Dual FXR/LTA4H Modulators

D. Steinhilber, E. Proschak, J. Kramer, 2021, ChemMedChem.

Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γ Agonists/Soluble Epoxide Hydrolase Inhibitors.

S. Knapp, D. Steinhilber, E. Proschak, 2021, Journal of medicinal chemistry.

Structure optimization of a new class of PPARγ antagonists.

D. Steinhilber, M. Schubert-Zsilavecz, M. Wurglics, 2019, Bioorganic & medicinal chemistry.

A New FXR Ligand Chemotype with Agonist/Antagonist Switch.

D. Merk, A. Kaiser, Jurema Schmidt, 2021, ACS medicinal chemistry letters.

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists

E. Proschak, D. Merk, J. Marschner, 2022, International journal of molecular sciences.

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

E. Proschak, D. Merk, Pascal Heitel, 2019, ChemMedChem.

Beam Search for Automated Design and Scoring of Novel ROR Ligands with Machine Intelligence

G. Schneider, Michael Moret, F. Grisoni, 2021, Angewandte Chemie.

Beam Search Sampling for Molecular Design and Intrinsic Prioritization with Machine Intelligence

Gisbert Schneider, Francesca Grisoni, Michael Moret, 2021 .

Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.

E. Proschak, Jurema Schmidt, M. Helmstädter, 2021, Journal of medicinal chemistry.

Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

E. Proschak, Jurema Schmidt, M. Helmstädter, 2021, ACS pharmacology & translational science.